{"id":"formulation-e","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal discomfort"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL71572","moleculeType":"Small molecule","molecularWeight":"520.57"},"_dailymed":{"setId":"4d5c5b14-9e4f-4d43-a336-e4ae71d34e42","title":"TOVET (EMOLLIENT FORMULATION) (CLOBETASOL PROPIONATE) AEROSOL, FOAM [MEDIMETRIKS PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lyndra's Formulation E uses a proprietary geometry-based approach to create a capsule that unfolds and lodges in the stomach, allowing prolonged drug release over days or weeks. This enables less frequent dosing of medications that would normally require daily administration, improving patient adherence and reducing pill burden.","oneSentence":"Formulation E is a gastric-resident capsule that delivers oral medications in an extended-release manner by adhering to the stomach lining.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:32:42.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Extended-release oral drug delivery platform (non-indication-specific technology)"}]},"trialDetails":[{"nctId":"NCT06507904","phase":"PHASE1","title":"A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-09-15","conditions":"Healthy","enrollment":52},{"nctId":"NCT07015944","phase":"NA","title":"Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan","status":"RECRUITING","sponsor":"Pakistan Institute of Living and Learning","startDate":"2025-06-13","conditions":"Major Depressive Disorder (MDD), Breast Cancer Survivor","enrollment":26376},{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":160},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07455825","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Healthy Participants","enrollment":64},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":"Solid Tumors","enrollment":920},{"nctId":"NCT07226817","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-12","conditions":"Healthy Volunteers","enrollment":140},{"nctId":"NCT07445464","phase":"PHASE1","title":"An Open Label Pharmacokinetic Study of ASP-001 Formulations in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Aspartes Pharmaceuticals, Inc.","startDate":"2026-04-09","conditions":"Pharmacokinetic Analysis","enrollment":12},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75},{"nctId":"NCT07168915","phase":"PHASE1","title":"A Study of V118E in Healthy Participants (V118E-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Healthy","enrollment":126},{"nctId":"NCT05755932","phase":"PHASE3","title":"Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-14","conditions":"Mucociliary Clearance","enrollment":35},{"nctId":"NCT06685809","phase":"PHASE1","title":"A Phase 1 Study of FZ008-145 in Healthy Subjects.","status":"RECRUITING","sponsor":"Guangzhou Fermion Technology Co., LTD","startDate":"2024-11-25","conditions":"Healthy","enrollment":190},{"nctId":"NCT06619314","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-20","conditions":"Healthy","enrollment":56},{"nctId":"NCT07254286","phase":"PHASE1","title":"Food Effect Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Biomea Fusion Inc.","startDate":"2025-09-11","conditions":"Healthy Volunteer","enrollment":60},{"nctId":"NCT07016464","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants.","status":"TERMINATED","sponsor":"reMYND","startDate":"2025-03-20","conditions":"Healthy","enrollment":19},{"nctId":"NCT06625502","phase":"NA","title":"Unmute's CARE Framework: A Novel Approach to Strengthen the Therapeutic Alliance and Reduce Treatment Disparities","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York University","startDate":"2025-09-15","conditions":"Depression Scale Score, Anxiety Symptoms, Functioning, Psychosocial","enrollment":40},{"nctId":"NCT07132983","phase":"PHASE2","title":"A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2025-10-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":33},{"nctId":"NCT07316608","phase":"PHASE1","title":"A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-16","conditions":"Healthy Participants","enrollment":44},{"nctId":"NCT07301515","phase":"NA","title":"Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin","status":"COMPLETED","sponsor":"Klira Skin","startDate":"2025-03-01","conditions":"Photoaging, Photodamage, Mitochondrial Damage","enrollment":52},{"nctId":"NCT05418868","phase":"PHASE1","title":"A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2022-06-14","conditions":"HIV Infections","enrollment":214},{"nctId":"NCT06686654","phase":"PHASE1, PHASE2","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-11","conditions":"Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization","enrollment":1530},{"nctId":"NCT07250594","phase":"PHASE2","title":"A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma","status":"NOT_YET_RECRUITING","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2025-12","conditions":"Eosinophilic Asthma","enrollment":126},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT03656718","phase":"PHASE1, PHASE2","title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-29","conditions":"Neoplasms by Site","enrollment":139},{"nctId":"NCT03910972","phase":"PHASE1, PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":"Schistosomiasis, Schistosoma Mansoni","enrollment":290},{"nctId":"NCT05662033","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-05","conditions":"Inflammatory Diseases","enrollment":93},{"nctId":"NCT06484335","phase":"PHASE1","title":"RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-03-27","conditions":"HIV Infections, PLWH, ART","enrollment":48},{"nctId":"NCT04088721","phase":"PHASE1, PHASE2","title":"Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2019-03-26","conditions":"Allergic Rhinitis","enrollment":48},{"nctId":"NCT05985694","phase":"PHASE1, PHASE2","title":"AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2023-11-27","conditions":"Eosinophilic Asthma","enrollment":40},{"nctId":"NCT05541510","phase":"PHASE2, PHASE3","title":"Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19","status":"TERMINATED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2022-12-01","conditions":"COVID-19","enrollment":180},{"nctId":"NCT04131556","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants","status":"TERMINATED","sponsor":"Shire","startDate":"2019-10-25","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT05178134","phase":"PHASE2","title":"A Phase 2 Bridging Study to Assess the New Formulation of ETVAX","status":"COMPLETED","sponsor":"Scandinavian Biopharma AB","startDate":"2021-11-08","conditions":"Healty Volunteers, Preventable Disease, Vaccine","enrollment":280},{"nctId":"NCT06702449","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-19","conditions":"Urinary Tract Infections","enrollment":448},{"nctId":"NCT04658667","phase":"PHASE1","title":"HIV Vaccine in HIV-uninfected Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-02-03","conditions":"HIV","enrollment":81},{"nctId":"NCT06456073","phase":"PHASE1","title":"E-CEL UVEC Treatment for Anal Fissures","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-09-12","conditions":"Chronic Anal Fissure","enrollment":12},{"nctId":"NCT06948006","phase":"PHASE1","title":"A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-04-23","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT05767905","phase":"PHASE1","title":"A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-17","conditions":"Healthy","enrollment":18},{"nctId":"NCT05263895","phase":"PHASE1","title":"Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-03","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT07007546","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants","status":"RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2025-05-17","conditions":"Healthy","enrollment":42},{"nctId":"NCT06990152","phase":"NA","title":"A Randomized, Double-blind Clinical Trial on the Efficacy of a Dietary Formulation Containing Medium-chain Triglycerides (MCT) and Fiber in Patients With Psoriatic Arthritis","status":"RECRUITING","sponsor":"Dr. Schär AG / SPA","startDate":"2025-05-16","conditions":"Psoriatic Arthritis (PsA)","enrollment":60},{"nctId":"NCT06853197","phase":"NA","title":"Bioavailability of Seven Mitopure Formulations","status":"COMPLETED","sponsor":"Amazentis SA","startDate":"2025-03-17","conditions":"Healthy Adults","enrollment":84},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT03649997","phase":"PHASE1","title":"A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-08-28","conditions":"Healthy","enrollment":57},{"nctId":"NCT04033458","phase":"PHASE1","title":"A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-29","conditions":"Healthy","enrollment":1},{"nctId":"NCT03682380","phase":"PHASE1","title":"A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-01","conditions":"Healthy","enrollment":151},{"nctId":"NCT04566926","phase":"PHASE1","title":"A Study of JNJ-64140284 in Healthy Male Participants","status":"TERMINATED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-09-29","conditions":"Healthy","enrollment":33},{"nctId":"NCT03438461","phase":"PHASE1","title":"A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-09","conditions":"Healthy","enrollment":49},{"nctId":"NCT06362018","phase":"NA","title":"Bioavailability of Five Mitopure Formulations","status":"COMPLETED","sponsor":"Amazentis SA","startDate":"2024-05-07","conditions":"Healthy Adults","enrollment":60},{"nctId":"NCT04961541","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2021-09-08","conditions":"SARS-CoV Infection, Covid19","enrollment":637},{"nctId":"NCT04448964","phase":"PHASE1","title":"A Study of JNJ-70033093 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT05112939","phase":"PHASE1","title":"A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-16","conditions":"Healthy","enrollment":126},{"nctId":"NCT03892616","phase":"PHASE1","title":"A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-04-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT06827587","phase":"NA","title":"Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-02","conditions":"Myasthenia Gravis, Autoimmune Diseases, Neuromuscular Diseases","enrollment":60},{"nctId":"NCT03416530","phase":"PHASE1","title":"ONC201 in Pediatric H3 K27M Gliomas","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2018-01-25","conditions":"Diffuse Intrinsic Pontine Glioma, Glioma, Malignant","enrollment":134},{"nctId":"NCT03010059","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-02-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT02659735","phase":"PHASE1","title":"A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-12","conditions":"Influenza A Virus","enrollment":90},{"nctId":"NCT02813460","phase":"PHASE1","title":"Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-06","conditions":"Healthy","enrollment":11},{"nctId":"NCT02561936","phase":"PHASE1","title":"Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-10","conditions":"Healthy","enrollment":32},{"nctId":"NCT03127189","phase":"PHASE1","title":"A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-20","conditions":"Healthy","enrollment":110},{"nctId":"NCT02608320","phase":"PHASE1","title":"A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-17","conditions":"Healthy","enrollment":52},{"nctId":"NCT05423106","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study of JNJ-64457744","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-04","conditions":"Healthy, Hepatitis B, Chronic","enrollment":60},{"nctId":"NCT04087759","phase":"PHASE1","title":"A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-16","conditions":"Healthy","enrollment":36},{"nctId":"NCT04421378","phase":"PHASE1, PHASE2","title":"A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-06-08","conditions":"Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT05708183","phase":"","title":"Healthy Mums, Healthy Babies: Multiple Micronutrient Supplementation in Ethiopia","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2023-01-01","conditions":"Birth Weight","enrollment":25620},{"nctId":"NCT06726278","phase":"NA","title":"Significance of Misoprostol-induced Cervical Ripening Prior to Hysteroscopy","status":"COMPLETED","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2022-08-01","conditions":"Hysteroscopy, Cervical Ripening","enrollment":539},{"nctId":"NCT04513015","phase":"NA","title":"Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach","status":"ACTIVE_NOT_RECRUITING","sponsor":"Università Politecnica delle Marche","startDate":"2019-12-15","conditions":"Inflammatory Bowel Diseases","enrollment":155},{"nctId":"NCT06659016","phase":"PHASE4","title":"Efficacy of Collagen, Propolis Plus Quercetin (Proqutin®), Bacillus Coagulans, Hyaluronic Acid and Chondroitin Sulphate and D-Mannose to Avoid Symptoms and Prevents Recurrence in Women With Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2023-02-01","conditions":"Urinary Tract Infection (Diagnosis)","enrollment":148},{"nctId":"NCT05852340","phase":"PHASE1","title":"A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-09","conditions":"Healthy Volunteers, Adult, Pharmacokinetics","enrollment":12},{"nctId":"NCT06477926","phase":"PHASE1","title":"A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-07-09","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT05918822","phase":"PHASE1","title":"A Study of Maribavir Pediatric Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-07-25","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT03146273","phase":"NA","title":"Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)","status":"COMPLETED","sponsor":"Galilee CBR","startDate":"2017-05-09","conditions":"Vitamin Deficiency","enrollment":20},{"nctId":"NCT05525910","phase":"PHASE1","title":"Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-31","conditions":"Biological Availability, Healthy Participants","enrollment":15},{"nctId":"NCT04528719","phase":"PHASE1","title":"A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-09-30","conditions":"Respiratory Syncytial Virus","enrollment":651},{"nctId":"NCT02629419","phase":"PHASE2","title":"CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2016-09-27","conditions":"Candidiasis, Chronic Mucocutaneous","enrollment":4},{"nctId":"NCT06168318","phase":"PHASE1","title":"A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2023-12-18","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT05519839","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-12-30","conditions":"COVID-19, Influenza","enrollment":1579},{"nctId":"NCT04071821","phase":"PHASE1","title":"Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg","status":"NOT_YET_RECRUITING","sponsor":"Seattle Gummy Company","startDate":"2025-05-01","conditions":"Allergy","enrollment":30},{"nctId":"NCT05129891","phase":"PHASE1","title":"A Research Study Looking at New Protein-based Tablets in Healthy Male Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-03","conditions":"Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes","enrollment":384},{"nctId":"NCT06370104","phase":"NA","title":"Treating Suicidality Remotely","status":"RECRUITING","sponsor":"113 Suicide Prevention","startDate":"2024-05-07","conditions":"Suicide Attempt","enrollment":364},{"nctId":"NCT04726332","phase":"PHASE1","title":"Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)","status":"TERMINATED","sponsor":"Exelixis","startDate":"2021-02-10","conditions":"Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer","enrollment":52},{"nctId":"NCT05769569","phase":"PHASE1","title":"Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2023-09-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT06355765","phase":"","title":"Citicoline & Antioxidants in Glaucoma","status":"COMPLETED","sponsor":"University of Naples","startDate":"2022-01-10","conditions":"Glaucoma, Open-Angle","enrollment":60},{"nctId":"NCT06360445","phase":"PHASE1","title":"Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2022-05-26","conditions":"Healthy Participants","enrollment":102},{"nctId":"NCT02741947","phase":"PHASE4","title":"Levodopa Benserazide Generic Formulation Versus the Originator","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2014-04","conditions":"Parkinson Disease","enrollment":44},{"nctId":"NCT05431153","phase":"PHASE1","title":"A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT05454462","phase":"PHASE1","title":"KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)","status":"COMPLETED","sponsor":"Kamari Pharma Ltd","startDate":"2022-05-24","conditions":"Lichen Simplex Chronicus","enrollment":55},{"nctId":"NCT06318052","phase":"NA","title":"The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM)","status":"UNKNOWN","sponsor":"Lumenis Be Ltd.","startDate":"2019-11-01","conditions":"Vaginal Atrophy Patients With GSM","enrollment":68},{"nctId":"NCT05630677","phase":"PHASE1","title":"A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-11-04","conditions":"Healthy Volunteers","enrollment":21},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04747301","phase":"NA","title":"DOuble-BAlloon Versus PROstaglandin E2 for Cervical Ripening in Low Risk Pregnancies","status":"UNKNOWN","sponsor":"Hanoi Obstetrics and Gynecology Hospital","startDate":"2021-08-01","conditions":"Induction of Labor","enrollment":540},{"nctId":"NCT06181045","phase":"PHASE1","title":"A Study of LY3410738 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT04223960","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants","status":"COMPLETED","sponsor":"EA Pharma Co., Ltd.","startDate":"2020-01-09","conditions":"Healthy Volunteers","enrollment":184},{"nctId":"NCT06181084","phase":"PHASE1","title":"A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-11","conditions":"Healthy","enrollment":60},{"nctId":"NCT05069610","phase":"PHASE1, PHASE2","title":"Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2022-03-21","conditions":"COVID-19","enrollment":30},{"nctId":"NCT05137730","phase":"PHASE1","title":"A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-11-29","conditions":"Healthy Volunteers","enrollment":96},{"nctId":"NCT04134091","phase":"PHASE2","title":"The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2019-08-27","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":56},{"nctId":"NCT06159452","phase":"PHASE1","title":"Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07-09","conditions":"Rheumatoid Arthritis","enrollment":53},{"nctId":"NCT05812950","phase":"NA","title":"Clinical and Cost-effectiveness of Group Schema Therapy for Complex Eating Disorders: the GST-EAT Study","status":"RECRUITING","sponsor":"Maastricht University","startDate":"2023-07-24","conditions":"Anorexia Nervosa, Atypical Anorexia Nervosa (Other Specified Eating Disorder), Bulimia Nervosa","enrollment":230},{"nctId":"NCT05512806","phase":"PHASE1","title":"A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-08-24","conditions":"Healthy Participants","enrollment":16},{"nctId":"NCT04524832","phase":"PHASE1","title":"Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-09-29","conditions":"Diabetes Mellitus, Type 2","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":90,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo capsule","nosocomial pneumonia","MIC","JNJ-53718678"],"phase":"marketed","status":"active","brandName":"Formulation E","genericName":"Formulation E","companyName":"Lyndra Inc.","companyId":"lyndra-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formulation E is a gastric-resident capsule that delivers oral medications in an extended-release manner by adhering to the stomach lining. Used for Extended-release oral drug delivery platform (non-indication-specific technology).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}